← Back to headlines
Antengene Receives Australian Approval for Phase I ATTRACT Study
Antengene has received clinical trial approval in Australia for its Phase I ATTRACT Study of ATG-201, targeting B cell-related autoimmune diseases.
25 Aug, 00:30 — 25 Aug, 00:30
Related Stories
IMF Chief Warns Global Economy Faces Energy Shocks and Fiscal Pressures
14m ago
Abercrombie & Fitch Shares Surge on Strong Second-Quarter Earnings and Raised Guidance
29m ago
TWG Global Denies Fraud Allegations and Lakers Fire Sale Rumors Amid Federal Probe
33m ago
Montenegro Official Rejects Alleged Political Pressure Attempts
36m ago